Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Cartwright

Interventional Pain Medicine St Augustine, FL Medical Doctor

NPI 1265659460 CMS profile 485591

105 Whitehall Dr Ste 115&116, St Augustine, FL 32086

Open in the dashboard

General payments

$17,850

572 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Cartwright of St Augustine, FL is reported in the CMS Open Payments database as having received $17,850 across 572 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,952 78
2024 General $2,555 80
2023 General $2,918 96
2022 General $3,602 90
2021 General $2,784 98
2020 General $1,006 50
2019 General $2,033 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Cartwright
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Joseph Cartwright were reported at $2,952. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Joseph Cartwright Interventional Pain Medicine median Middle half National median
2019 $2,033 $684 $216–$2,079 $163
2020 $1,006 $382 $122–$1,109 $114
2021 $2,784 $552 $167–$1,554 $132
2022 $3,602 $605 $187–$1,924 $149
2023 $2,918 $671 $195–$1,915 $160
2024 $2,555 $684 $206–$1,837 $164
2025 $2,952 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $6,938 119 payments
  2. AbbVie, Inc. $1,903 122 payments
  3. Nevro Corp. $1,207 24 payments
  4. Relievant Medsystems, Inc. $751 11 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $694 39 payments
  6. Abbott Laboratories $477 17 payments
  7. Medtronic, Inc. $473 8 payments
  8. Collegium Pharmaceutical, Inc. $457 28 payments
  9. SPR Therapeutics, Inc $376 6 payments
  10. Pfizer Inc. $373 24 payments
  11. Other $4,199 174 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,968 564 payments
  2. Travel and Lodging $1,865 7 payments
  3. Education $17 1 payment
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $2,610 52 payments
  2. Superion Indirect Decompression System $1,632 13 payments
  3. UBRELVY $1,399 90 payments
  4. QULIPTA $905 55 payments
  5. WAVEWRITER ALPHA $887 5 payments
  6. Intracept Pain $751 11 payments
  7. Intracept Pain $751 11 payments
  8. Intracept Pain $751 11 payments
  9. Intracept Pain $751 11 payments
  10. RELISTOR $656 37 payments
  11. Other $10,735 387 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

8,113

Median for Interventional Pain Management: 1,220

Drug cost

$398,817

Median for Interventional Pain Management: $39,344

Branded share of claims

37.9%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Relistor Methylnaltrexone Bromide Brand 24 $57,546
Nucynta Er Tapentadol Hcl Brand 30 $56,152
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,224 $46,156
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,314 $33,426
Ubrelvy Ubrogepant Brand 21 $33,406
Oxycontin Oxycodone Hcl Brand 38 $27,623
Movantik Naloxegol Oxalate Brand 38 $15,084
Qulipta Atogepant Brand 13 $14,976
Gabapentin Generic 747 $12,296
Oxycodone Hcl Generic 565 $10,444

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$1,371,038

Of which drugs: $69,293

Medicare patients

685

Average age 74

Services billed

31,971

386 women, 299 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 38%
Depression 29%
Diabetes 26%
Chronic kidney disease 24%
Atrial fibrillation 20%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 16 7,775 $38,758
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 39 59 $23,799
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 382 3,443 $2,609
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 258 3,650 $324

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $191
$191 21 —
QULIPTA
  • AbbVie, Inc. $191
$191 13 —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $131
$131 11 —
NURTEC ODT
  • PFIZER INC. $87
$87 — —
ZAVZPRET
  • PFIZER INC. $87
$87 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

572 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record